Research Article

Risk Factors for Gastric Cancer-Associated Thrombotic Diseases in a Han Chinese Population

Bo Song,1 Yamei Wang,2 Xiuzhi Zhu,3 Li Zhang,2 Hui Zhou,2 Hongmei Zhang,2 Tianliang Zhang,4 and Wansheng Ji2

1Department of Gastroenterology, Yantaishan Hospital, Yantai 264001, China
2Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, Weifang Medical University, Weifang 261031, China
3Department of Respiratory Medicine, Changle People’s Hospital, Weifang 262400, China
4Experimental Center for Medical Research, Weifang Medical University, Weifang 261053, China

Correspondence should be addressed to Tianliang Zhang; burke1981@163.com and Wansheng Ji; jiwsh@wfmc.edu.cn

Received 26 February 2021; Revised 8 May 2021; Accepted 12 May 2021; Published 22 May 2021

Academic Editor: Celal Ulasoglu

Copyright © 2021 Bo Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of the present work was to investigate the risk factors for gastric cancer- (GC-) associated thrombotic diseases in a Han Chinese population. A total of 333 patients diagnosed with GC, 68 with thrombotic diseases included in the case group and the remaining 265 in the control group, were enrolled. The relevant data for the participants, including general information (gender, age, smoking, and drinking), comorbidities (diabetes, hypertension, and anemia), tumor-related data (tumor site, histology, degree of differentiation, and clinical stage), and treatment-related data (surgery, chemotherapy, hormones, transfusion, and peripherally inserted central venous catheter (PICC)), were collected. Statistically significant factors derived from univariate analyses were then subjected to multivariate logistic regression analyses. The results demonstrate a statistically significant difference in age, diabetes, surgery, and PICC (P < 0.05), compared with control. Age, diabetes, surgery, and PICC serve as independent risk factors for GC-associated thrombotic diseases (P < 0.05). The present work demonstrates that GC-associated thrombotic diseases are significantly associated with age, diabetes, surgery, and PICC, suggesting a potential target for early detection and preventive strategy for GC patients with thrombophilia.

1. Introduction

Gastric cancer (GC) is the most common malignancy in the upper digestive tract [1, 2]. In 2018, GC possessed the fifth incidence rate and third mortality among cancers worldwide [3]. GC-associated complications, with gastrointestinal bleeding as the most common one, seriously affect the treatment and prognosis for patients. As one of the cancer-associated complications, thromboembolism has become the second leading cause of death in patients with cancers [4]. Therefore, it is vital to pay special attention to cancer patients complicated with thromboembolism in a clinical work.

About 8–19% of cancer patients are subjected to thrombosis which is called cancer-associated thrombosis (CAT), with the majority occurring within 3 months after definite diagnosis of cancer [5]. Diseases derived from the pathological processes of thrombosis or thromboembolism are collectively regarded as thrombotic diseases in clinical practice [6]. Thrombosis leads to stenosis of vascular lumen and obstruction to blood flow, and thromboembolism is likely to increase the risk for stroke, pulmonary embolism, and cardiogenic shock. Thrombosis and thromboembolism are closely related to tumor progression, angiogenesis, and metastasis; CAT, with its increasing incidence rate in recent years, seriously affects the treatment and prognosis of cancers. This reflects an increase in cancer patients, as well as the improved clinical knowledge on CAT and diagnostic level [7, 8]. It has been found that 50–70% of cancer patients demonstrate hypercoagulable blood [9, 10]. The risk for venous thromboembolism
Thrombotic diseases exhibit no specific clinical symptoms in the early stage, which greatly affects the treatment and prognosis for cancer patients. Therefore, it is not advisable to diagnose thrombotic diseases only based on clinical symptoms. We must pay special attention to the early diagnosis and prevention of thrombophilic cancer patients. At present, researches on CAT mainly focus on VTE, with few on arterial thrombosis, however. In clinical, arterial thrombosis should not be ignored in cancer patients. The aim of the present study was to analyze the possible risk factors for GC-associated thrombotic diseases to provide theoretical support for early detection and preventive measures for GC patients with thrombophilia, so as to improve the treatment effects, clinical prognosis, and life quality.

2. Materials and Methods

2.1. Subjects. A total of 333 Han Chinese patients of Shandong origin, diagnosed with GC in the Affiliated Hospital of Weifang Medical University between September 2013 and September 2017, were enrolled in the present study. Among them, 68 patients complicated with thrombotic diseases were included in the case group and the remaining 265 in the control group. All participants signed written informed consent regarding the present study which was approved by the Ethics Committee of Weifang Medical University.

The inclusion criteria were as follows: (1) all participants were diagnosed as GC by pathology. (2) Patients from the case group were diagnosed with thrombotic diseases by imaging or ultrasound examination, with the diagnosis posterior to that of GC. There was no clinical manifestation or thrombosis confirmed by imaging examination for healthy controls. (3) Complete clinical data were available.

The exclusion criteria were as follows: (1) GC not confirmed by pathology, (2) primary thrombotic diseases, (3) suffering from coagulation dysfunction or used drugs affecting coagulation function recently, (4) combined with other cancers or hematological diseases, and (5) incomplete clinical data.

2.2. Data Collection. The clinical data for the participants, including patient-related factors (gender, age, smoking, drinking, diabetes, hypertension, and anemia), cancer-related factors (histology, degree of differentiation, tumor site, and clinical stage), and treatment-related factors (surgery, chemotherapy, hormone, transfusion, and peripherally inserted central venous catheter (PICC)), were collected.

2.3. Statistical Analyses. Statistical analyses were carried out by SPSS 17.0. The measurement data were expressed as the means ± standard deviation, with the counting data presented as rate or composition ratio. And the univariate analyses were performed, and \( \chi^2 \) test or rank test was employed. Multivariate logistic regression analyses were conducted on the factors with statistical significance. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. Basic Information. As is presented in Figure 1, the location and case counts for thrombosis are as follows: 37 cases with cerebral infarction, 2 with myocardial infarction, 1 with renal aortic thrombosis, 1 with abdominal aortic thrombosis, 19 with upper and lower extremity venous thrombosis, 7 with portal vein thrombosis, and 1 with splenic vein thrombosis (Figure 1). Arterial and venous thrombosis accounts for 60.29% and 39.71%, respectively. The clinical manifestations for patients from the case group include the following: fatigue and anorexia (\( n = 8 \)), indigestion and abdominal pain (\( n = 19 \)), nausea and vomiting (\( n = 5 \)), dizziness (\( n = 3 \)), palpitations and chest tightness (\( n = 2 \)), recurrent dizziness and headache (\( n = 6 \)), upper limb swelling with pain (\( n = 4 \)), unilateral lower limb swelling with pain (\( n = 7 \)), bilateral lower limb swelling with pain (\( n = 8 \)), and no obvious clinical manifestation (\( n = 6 \)).

3.2. Univariate Analyses. As is shown in Table 1, univariate analyses show that age, diabetes, hypertension, histology, surgery, chemotherapy, and PICC are significantly different between the case and control groups (\( P < 0.05 \)). No significant difference between the two was found in the degree of differentiation or GC stage, however (Table 2).

3.3. Multivariate Logistic Regression Analyses. The factors with \( P < 0.05 \) in Table 1 were regarded as the independent variable, with the occurrence of thrombosis as the dependent one. The results of multivariate logistic regression analyses show that age ≥ 60, diabetes, surgery, and PICC serve as independent risk factors for GC complicated with thrombotic diseases (\( P < 0.05 \)) (Table 3).
Table 1: Univariate analyses on gastric cancer patients complicated with thrombotic diseases.

| Factors                  | Case group (n = 68) | Control group (n = 265) | χ² value | P value |
|--------------------------|--------------------|-------------------------|----------|---------|
| **Patient-related factors** |                    |                         |          |         |
| Gender                   |                    |                         |          |         |
| Male                     | 52 (76.47%)        | 186 (70.19%)            | 1.047    | 0.306   |
| Female                   | 16 (23.53%)        | 79 (29.81%)             |          |         |
| Age                      |                    |                         | 4.144    | 0.042   |
| <60                      | 21 (30.88%)        | 118 (44.53%)            |          |         |
| ≥60                      | 47 (69.12%)        | 147 (55.47%)            |          |         |
| Smoking                  |                    |                         | 0.790    | 0.374   |
| Yes                      | 29 (42.65%)        | 129 (48.68%)            |          |         |
| No                       | 39 (57.35%)        | 136 (51.32%)            |          |         |
| Drinking                 |                    |                         | 0.646    | 0.422   |
| Yes                      | 18 (26.47%)        | 58 (21.89%)             |          |         |
| No                       | 50 (73.53%)        | 207 (78.11%)            |          |         |
| Diabetes                 |                    |                         | 4.652    | 0.031   |
| Yes                      | 8 (11.76%)         | 63 (23.77%)             |          |         |
| No                       | 60 (88.24%)        | 202 (76.23%)            |          |         |
| Hypertension             |                    |                         | 3.979    | 0.046   |
| Yes                      | 19 (27.94%)        | 109 (41.13%)            |          |         |
| No                       | 49 (72.06%)        | 156 (58.87%)            |          |         |
| Anemia                   |                    |                         | 0.005    | 0.945   |
| Yes                      | 27 (39.71%)        | 104 (39.25%)            |          |         |
| No                       | 41 (60.29%)        | 161 (60.75%)            |          |         |
| **Cancer-related factors** |                    |                         |          |         |
| Histology                |                    |                         | 4.238    | 0.040   |
| Adenocarcinoma           | 50 (73.53%)        | 159 (60.00%)            |          |         |
| Non-adenocarcinoma       | 8 (26.47%)         | 106 (40.00%)            |          |         |
| Cancer site              |                    |                         | 4.780    | 0.189   |
| Cardia and fundus        | 14 (20.59%)        | 54 (20.38%)             |          |         |
| Corpus                   | 19 (27.94%)        | 71 (26.79%)             |          |         |
| Angle                    | 12 (17.65%)        | 77 (29.06%)             |          |         |
| Pylorus                  | 23 (33.82%)        | 63 (23.77%)             |          |         |
| **Treatment-related factors** |                   |                         |          |         |
| Surgery                  |                    |                         | 4.482    | 0.034   |
| Yes                      | 33 (48.53%)        | 166 (62.64%)            |          |         |
| No                       | 35 (51.47%)        | 99 (37.36%)             |          |         |
| Chemotherapy             |                    |                         | 4.069    | 0.044   |
| Yes                      | 29 (42.65%)        | 79 (29.81%)             |          |         |
| No                       | 39 (57.35%)        | 186 (70.19%)            |          |         |
| Hormone                  |                    |                         | 0.859    | 0.354   |
| Yes                      | 14 (20.59%)        | 69 (26.04%)             |          |         |
| No                       | 54 (79.41%)        | 196 (73.96%)            |          |         |
| Transfusion              |                    |                         | 2.793    | 0.095   |
| Yes                      | 10 (14.71%)        | 64 (24.15%)             |          |         |
| No                       | 58 (85.29%)        | 201 (75.85%)            |          |         |
| PICC                     |                    |                         | 4.032    | 0.045   |
| Yes                      | 12 (17.65%)        | 79 (29.814%)            |          |         |
| No                       | 56 (82.35%)        | 186 (70.19%)            |          |         |
4. Discussion

GC, one of the most common malignant and thrombogenic tumors, may be responsible for the increasing incidence of CAT [13] which is affected by a variety of factors [14]. So far, studies on CAT mainly focus on VTE, with few on arterial thrombosis, however. Therefore, it is also vital to investigate the role of arterial thrombosis in CAT. With the major type as cerebral infarction (CI), arterial thrombosis accounts for 60.3% in the present work, suggesting its significance. Some factors, such as age, diabetes, and hypertension, may be involved in the occurrence of CI [15–19]. Therefore, it is uncertain whether the CI is caused by the aforementioned factors or cancer itself. It has been suggested that CI occurs more frequently in cancer patients than in normal ones [20]. And numerous recent studies report a very similar incidence of CI between cancer and noncancer patients. Contradictory conclusions were drawn from different studies [21–24]. Further researches are needed to clarify the underlying mechanisms.

The present work shows that age, diabetes, surgery, and PICC are independent risk factors for GC patients complicated with thrombotic diseases. It has been reported that age, an important risk factor for CAT formation, is inversely correlated with its incidence [25]. As generally acknowledged, the aged might have less smooth vessel wall, higher blood viscosity, and relatively lower blood flow velocity [26, 27]. However, few reports exhibit no statistical difference in age [28]. These contradictory findings may be due to heterogeneity, sampling error, and younger onset age for GC.

Cancer patients with diabetes mellitus are prone to thromboembolism. The possible reasons are as follows. Firstly, blood glucose can easily lead to atherosclerosis of vascular wall and cause microcirculation disorder when it invades peripheral arteries, thus affecting blood flow of limbs and resulting in thrombosis [29]. Secondly, the state of high blood glucose in diabetic patients can give rise to oxidative stress, which leads to vascular endothelial cell dysfunction as well as an abnormal anticoagulant and fibrinolytic system [30]. Moreover, the high blood glucose reduces the deformability while it increases the aggregation of red blood cells, respectively. This results in abnormal aggregation and disaggregation for red blood cells and damaged walls of blood vessels, which contributes to thromboembolism [31].

Some researchers have proposed that the risk for thrombosis in malignant tumors depends on tumor type, stage, and antitumor drugs employed [32]. And the risk for VTE in adenocarcinoma is three times more than that in squamous cell carcinoma [33], probably due to the excessive expression of procoagulant factors in adenocarcinoma [34]. Various studies have reported that factors related to cancer treatment, such as surgery, radiotherapy, and chemotherapy, also increase the risk for thrombosis [35, 36]. Up to date, surgery is still the foremost means to treat cancers and the probability of thrombosis after surgery is about 40% [37], with the early mortality rate as high as 3.89% [38]. In order to prevent the occurrence of thrombosis, the risk for thromboembolism should be cautiously evaluated before and after surgery.

### Table 2: Univariate analyses on gastric cancer patients complicated with thrombotic diseases.

| Factors          | Case group (n = 68) | Control group (n = 265) | Z value | P value |
|------------------|---------------------|-------------------------|---------|---------|
| Degree of differentiaion |                     |                         |         |         |
| High             | 19 (27.94%)         | 76 (28.68%)             | -1.604  | 0.109   |
| Moderate         | 23 (33.82%)         | 51 (19.25%)             |         |         |
| Low              | 26 (38.24%)         | 138 (52.08%)            |         |         |

### Table 3: Multivariate logistic regression analyses on gastric cancer patients complicated with thrombotic diseases.

| Factors | B      | SE      | Wald   | P value | OR     | 95% CI Lower limit | 95% CI Upper limit |
|---------|--------|---------|--------|---------|--------|--------------------|--------------------|
| Age ≥ 60| 0.623  | 0.295   | 4.478  | 0.035   | 1.865  | 1.046              | 3.324              |
| Diabetes| 0.941  | 0.335   | 7.917  | 0.005   | 2.564  | 1.331              | 4.940              |
| Hypertension| 0.307  | 0.280   | 1.202  | 0.273   | 1.360  | 0.785              | 2.355              |
| Adenocarcinoma| -0.537 | 0.303   | 3.149  | 0.076   | 0.585  | 0.323              | 1.058              |
| Surgery| 0.698  | 0.283   | 6.095  | 0.014   | 2.010  | 1.155              | 3.499              |
| Chemotherapy| 0.523  | 0.274   | 3.634  | 0.057   | 1.687  | 0.985              | 2.889              |
| PICC    | 0.892  | 0.343   | 6.751  | 0.009   | 2.441  | 1.245              | 4.784              |
Central vein catheter, used for blood sampling, chemotherapeutic drug infusion, intravenous nutrition, and clinical monitoring, can be divided into three categories, with PICC most widely used [39, 40]. It brings convenience to cancer patients but increases the risk for thromboembolism meanwhile [4]. To a certain extent, the implantation of PICC tube directly impairs the vascular endothelium, and the intravenous infusion of chemotherapy drugs can also stimulate and impair the blood vessels. That results in decreased elasticity of blood vessels, increased fragility, and thinner vascular walls, which increases the risk for thromboembolism. Antithrombotic measures are important since VTE definitely affects mortality. And cases with PICC and/or diabetes, along with operated ones, should not be neglected for preventive treatment.

The present study has several limitations: relatively small sample size, single center study, and shortage of follow-up. And the strength of the present work is that the arterial thrombosis was included in gastric cancer-associated thrombotic diseases, not like many previous ones which mainly focus on VTE.

In summary, the present work suggests that GC-associated thrombotic diseases are significantly associated with age, diabetes, surgery, and PICC in a Han Chinese population of Shandong origin, which provides a potential target for early detection and preventive strategy for GC patients with thrombophilia. And further multicentric studies employing a larger sample size are required to verify the findings.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Bo Song, Yamei Wang, and Xiuzhi Zhu contributed equally as co-first authors.

Acknowedgments

This work was funded by Shandong Provincial Award Foundation for Youth and Middle-aged Scientist (Grant No. BS2010SW034).

References

[1] A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, “Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy,” Journal of thrombosis and haemostasis: JTH, vol. 5, no. 3, pp. 632–634, 2007.

[2] M. Di Nisio, N. Ferrante, B. Feragalli et al., “Arterial thrombosis in ambulatory cancer patients treated with chemotherapy,” Thrombosis Research, vol. 127, no. 4, pp. 382-383, 2011.

[3] A. Falanga, M. Marchetti, and A. Vignoli, “Coagulation and cancer: biological and clinical aspects,” Journal of thrombosis and haemostasis: JTH, vol. 11, no. 2, pp. 223–233, 2013.

[4] J. F. Timp, S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter, “Epidemiology of cancer-associated venous thrombosis,” Blood, vol. 2013, p. 122, 2013.

[5] A. A. Khorana, M. Dalal, J. Lin, and G. C. Connolly, “Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States,” Cancer, vol. 119, no. 3, pp. 648–655, 2013.

[6] G. H. Lyman, “Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis,” Cancer, vol. 117, no. 7, pp. 1334–1349, 2011.

[7] G. H. Lyman, “The incidence of venous thromboembolism in cancer patients: a real-world analysis,” Clinical advances in hematology & oncology: H&O, vol. 10, no. 1, pp. 40–42, 2012.

[8] L. A. Anderson, S. C. Moore, G. Gridley, B. J. Stone, and O. Landgren, “Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans,” Leukemia & Lymphoma, vol. 52, no. 5, pp. 764–770, 2011.

[9] W. Chen, Y. Zhang, Y. Yang, Z. Zhai, and C. Wang, “Prognostic significance of arterial and venous thrombosis in resected specimens for non-small cell lung cancer,” Thrombosis Research, vol. 136, no. 2, pp. 451–455, 2015.

[10] E. S. Diaz, A. E. Walts, B. Y. Karlan, and C. S. Walsh, “Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival,” Gynecologic Oncology, vol. 131, no. 3, pp. 541–545, 2013.

[11] L. K. Hicks, M. C. Cheung, K. Ding et al., “Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials,” Cancer, vol. 115, no. 23, pp. 5516–5525, 2009.

[12] S. Ikushima, R. Ono, K. Fukuda, M. Sakayori, N. Awano, and K. Kondo, “Trousseau’s syndrome: cancer-associated thrombosis,” Japanese Journal of Clinical Oncology, vol. 46, no. 3, pp. 204–208, 2016.

[13] H. E. Fuentes, D. M. Oramas, L. H. Paz, Y. Wang, X. A. Andrade, and A. J. Tafur, “Venous thromboembolism is an independent predictor of mortality among patients with gastric cancer,” Journal of Gastrointestinal Cancer, vol. 49, no. 4, pp. 415–421, 2018.

[14] J. A. Caprini, “Risk assessment as a guide for the prevention of the many faces of venous thromboembolism,” American Journal of Surgery, vol. 199, no. 1, pp. S3–10, 2010.

[15] P. D. Cloiston, L. M. DeAngelis, and J. B. Posner, “The spectrum of neurological disease in patients with systemic cancer,” Annals of Neurology, vol. 31, no. 3, pp. 268–273, 1992.

[16] F. Graus, L. R. Rogers, and J. B. Posner, “Cerebrovascular complications in patients with cancer,” Medicine, vol. 64, no. 1, pp. 16–35, 1985.

[17] O. A. Sveinsson, O. Kjartansson, and E. M. Valdimarsson, “Heilablöðpurð / heiladrep. Faraldsfræði, orsakir og einkenni,” Laeknabladid, vol. 2014, no. 5, pp. 271–279, 2014.

[18] K. Lindvig, H. Moller, J. Mosbeck, and O. M. Jensen, “The pattern of cancer in a large cohort of stroke patients,” International Journal of Epidemiology, vol. 19, no. 3, pp. 498–504, 1990.

[19] S. Chaturvedi, J. Ansell, and L. Recht, “Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?,” Stroke, vol. 25, no. 6, pp. 1215–1218, 1994.
[20] M. Tuzovic, J. Herrmann, C. Iliescu, K. Marmagkiolis, B. Ziaeian, and E. H. Yang, “Arterial thrombosis in patients with cancer,” Current Treatment Options in Cardiovascular Medicine, vol. 20, no. 5, p. 40, 2018.

[21] D. M. Cestari, D. M. Weine, K. S. Panagreas, A. Z. Segal, and L. M. DeAngelis, “Stroke in patients with cancer: incidence and etiology,” Neurology, vol. 62, no. 11, pp. 2025–2030, 2004.

[22] Y. Y. Zhang, D. K. Chan, D. Cordato, Q. Shen, and A. Z. Sheng, “Stroke risk factor, pattern and outcome in patients with cancer,” Acta Neurologica Scandinavica, vol. 114, no. 6, pp. 378–383, 2006.

[23] Y. Y. Zhang, D. Cordato, Q. Shen, A. Z. Sheng, W. T. Hung, and D. K. Chan, “Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study,” Cerebrovascular Diseases, vol. 23, no. 2-3, pp. 181–187, 2007.

[24] W. Grisold, S. Oberndorfer, and W. Struhal, “Stroke and cancer: a review,” Acta Neurologica Scandinavica, vol. 119, no. 1, pp. 1–16, 2009.

[25] W. H. Li, G. B. Liu, Q. Han et al., “Literature analysis of other diseases misdiagnosed as deep venous thrombosis of lower extremities in China in the past 20 years,” Clinical Misdiagnosis & Misherapy, vol. 29, pp. 64–66, 2016.

[26] L. Coppola, F. Caserta, D. De Lucia et al., “Blood viscosity and aging,” Archives of Gerontology and Geriatrics, vol. 31, no. 1, pp. 35–42, 2000.

[27] M. J. Simmonds, H. J. Meiselman, and O. K. Baskurt, “Blood rheology and aging,” Journal of geriatric cardiology : JGC, vol. 10, no. 3, pp. 291–301, 2013.

[28] S. Xiao, X. Geng, J. Zhao, and L. Fu, “Risk factors for potential pulmonary embolism in the patients with deep venous thrombosis: a retrospective study,” European journal of trauma and emergency surgery : official publication of the European Trauma Society, vol. 46, no. 2, pp. 419–424, 2020.

[29] E. Westein, T. Hoefer, and A. C. Calkin, “Thrombosis in diabetes: a shear flow effect?,” Clinical Science, vol. 131, no. 12, pp. 1245–1260, 2017.

[30] K. Torimoto, Y. Okada, and Y. Tanaka, “Type 2 diabetes and vascular endothelial dysfunction,” Journal of UOEH, vol. 40, no. 1, pp. 65–75, 2018.

[31] J. R. Byrnes and A. S. Wolberg, “Red blood cells in thrombosis,” Blood, vol. 2017, p. 130, 2017.

[32] D. J. Tiede, A. Tefferi, R. Kochhar, G. B. Thompson, and I. D. Hay, “Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking,” Cancer, vol. 73, no. 3, pp. 702–705, 1994.

[33] H. K. Chew, T. Wun, D. Harvey, H. Zhou, and R. H. White, “Incidence of venous thromboembolism and its effect on survival among patients with common cancers,” Archives of Internal Medicine, vol. 166, no. 4, pp. 458–464, 2006.

[34] A. P. Owens 3rd, J. R. Byrnes, and N. Mackman, “Hyperlipidemia, tissue factor, coagulation, and simvastatin,” Trends in Cardiovascular Medicine, vol. 24, no. 3, pp. 95–98, 2014.

[35] J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W. M. O’Fallon, and L. J. Melton 3rd., “Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study,” Archives of Internal Medicine, vol. 160, no. 6, pp. 809–815, 2000.

[36] M. D. Silverstein, J. A. Heit, D. N. Mohr, T. M. Petterson, W. M. O’Fallon, and L. J. Melton 3rd., “Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study,” Archives of Internal Medicine, vol. 158, no. 6, pp. 585–593, 1998.